Connect with us

Technology

High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market Landscape – Technavio

Published

on

NEW YORK, Jan. 31, 2025 /PRNewswire/ — Report with market evolution powered by AI – The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period. Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

High Throughput Screening (HTS) Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 12.12%

Market growth 2024-2028

USD 19.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

11.64

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Japan, China, Germany, and France

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

High-throughput screening (HTS) is a key trend in the life sciences sector, particularly in the areas of drug discovery and research for complex illnesses like cancer and neurological disorders. HTS allows for the rapid testing of large compound libraries using automated equipment such as robotic arms and microplate readers. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to analyze genomic data and chemical databases for target identification. Biotech startups and academic institutions are driving innovation in this field, with pharmaceutical corporations and research organizations collaborating to advance drug development. HTS is also used in stem cell research, toxicology, and open innovation models. HTS service providers offer instruments, software, and consumables to support this research. HTS is transforming the biopharmaceutical industry, enabling precision medicine and the repurposing of existing drugs for new indications. With advancements in technology, HTS is becoming more accessible to a wider range of organizations, including biotechnology startups and clinical trials. Despite these advancements, challenges remain, including false-positive findings and the need for specialized equipment maintenance. Overall, HTS is a vital tool in the global healthcare sector’s quest to develop new products and services for the detection and treatment of chronic diseases. 

The High Throughput Screening (HTS) market presents unique challenges for vendors due to its specialized nature and niche end-users. Brand and product visibility play a limited role in sales, and advertising and marketing are restricted. Key players in the industry recognize this issue and are promoting HTS through their websites and additional support materials. Thermo Fisher Scientific, for instance, provides explanatory documents, brochures, and interactive videos on YouTube to help end-users understand the technique better. Despite these efforts, there is a significant lack of awareness about HTS. Vendors must focus on improving their distribution networks to make these products readily available to end-users. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

High-throughput screening (HTS) is a crucial process in the biotechnology industry, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. The market for HTS is vast and diverse, with players including academic institutions, biotech startups, and pharmaceutical corporations. Challenges in this field include managing large data sets from compound libraries, dealing with false-positive findings, and maintaining specialized equipment. HTS involves the use of automation, robotics, and specialized instruments like microplate readers and high-resolution imaging systems. Data analytics is essential for making sense of the vast amounts of data generated. Machine learning and data management systems help in data organization, retrieval, integration, and storage. HTS is not just limited to pharmaceutical companies but also extends to the global healthcare sector, research organizations, and contract research organizations. Collaborative networks and HTS service providers play a significant role in driving innovation through open innovation models. HTS is also used in stem cell research, toxicology, and drug development. HTS involves various techniques like cell-based assays, lab-on-a-chip, and label-free technology. Biochemical screening and target identification are critical components of the HTS process. Drug repurposing initiatives, such as those from Relay Therapeutics, are gaining popularity in the biopharmaceutical industry due to their potential to bring new drugs to market faster and more cost-effectively. The HTS market is expected to grow significantly due to the increasing focus on precision medicine and the need for new drugs to address chronic diseases. Consumables, software, and services are essential products and services in the HTS market. The use of technology in HTS, such as automation and advanced detection techniques, is transforming the drug discovery process. Despite the challenges, the future of HTS looks promising, with advancements in technology and a growing focus on collaboration and open innovation models. The use of HTS in drug discovery and development is expected to revolutionize the way we approach complex illnesses and bring new treatments to market.In today’s fast-paced pharmaceutical and biotechnology industries, High Throughput Screening (HTS) has become a crucial tool for discovering new drugs and optimizing existing ones. However, the successful implementation of HTS relies heavily on the availability of skilled personnel. The shortage of trained professionals in this field can lead to non-compliance and improper screening of drug targets. Consequently, product failures and regulatory issues can result in significant financial losses for companies. This issue is particularly prevalent in developing countries, where the healthcare system lacks the necessary workforce to effectively utilize HTS technology. To mitigate this challenge, it is essential for organizations to invest in training and development programs for their staff, ensuring they have the necessary expertise to operate HTS equipment effectively and efficiently.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This high throughput screening (HTS) market report extensively covers market segmentation by  

Application 1.1 Target identification and validation1.2 Primary and secondary screening1.3 Toxicology assessment1.4 Stem cell researchEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 Academic and research institutes2.3 CROsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global high throughput screening (HTS) market is driven by the increasing need for target identification and validation in drug development. This process involves finding potential therapeutic targets for diseases or conditions without existing treatments or inadequate current options. Early and thorough target identification and validation establish a strong link to clinical trial success. Chronic diseases like cardiovascular diseases, cancer, and respiratory diseases, which have a high global prevalence, fuel the demand for new targets. Additionally, the growing pipeline for biological candidates, outsourcing from pharmaceutical companies, and regulatory agencies’ demand for accurate drug and process development details contribute to market expansion. Advanced bioinformatics tools, automated experimental designs, and AI/ML algorithms are enhancing target identification and validation, further boosting the segment’s growth. Consequently, these factors are expected to fuel the growth of the target identification and validation segment in the global high throughput screening market during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

High-throughput screening (HTS) is a critical technology in the global healthcare sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, often containing hundreds of thousands to millions of compounds, which are screened against disease targets using automated systems. These systems include robotic arms, microplate readers, and high-resolution imaging systems. Data analytics plays a crucial role in HTS, with data management systems, data storage, data organization, data retrieval, data integration, and chemical databases essential for processing and interpreting the vast amounts of data generated. Academic institutions, biotech startups, research organizations, and pharmaceutical corporations all contribute to the HTS market, with open innovation models facilitating collaboration and knowledge sharing. Drug repurposing, the process of discovering new uses for existing drugs, is also a significant application of HTS. The market for HTS is expected to grow significantly due to the increasing demand for new and effective treatments for various diseases.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, store, retrieve, integrate, and analyze genomic data and chemical databases. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives and biopharmaceutical industry leaders are leveraging HTS for precision medicine and target identification, while toxicology and stem cell research also benefit from this technology. The global healthcare sector continues to invest in HTS for drug discovery, clinical trials, and product development, driving the market for instruments, software, and consumables.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationTarget Identification And ValidationPrimary And Secondary ScreeningToxicology AssessmentStem Cell ResearchEnd-userPharmaceutical And Biotechnology CompaniesAcademic And Research InstitutesCROsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-throughput-screening-hts-market-to-grow-by-usd-19-9-billion-2024-2028-boosted-by-rising-rd-investments-with-ai-redefining-market-landscape—technavio-302364447.html

SOURCE Technavio

Continue Reading

Technology

Canada to advance global nature conservation and climate action at upcoming United Nations conferences

Published

on

By

OTTAWA, ON, Oct. 16, 2026 /CNW/ — In a more uncertain and increasingly unstable world, Canada is stepping up to build a safer and more resilient future. Addressing climate change and biodiversity loss requires ambitious action at home and around the world. By advancing progress on both, Canada will protect nature, build resilient communities, and create lasting prosperity for future generations. International cooperation is key to achieving these goals.

That is why the Honourable Julie Dabrusin, Minister of the Environment, Climate Change and Nature, will lead Canada’s efforts as Head of Delegation at the 17th meeting of the Conference of the Parties to the Convention on Biological Diversity (COP17) and the 31st meeting of the Conference of the Parties to the United Nations Framework Convention on Climate Change (COP31).

At COP17, Minister Dabrusin and the Honourable Nathalie Provost, Secretary of State (Nature), will work with international partners to accelerate implementation of the Kunming–Montréal Global Biodiversity Framework. From October 19 to 30, 2026, in Yerevan, Armenia, Canada will champion the critical role of Indigenous peoples in conservation and advocate for practical solutions to mobilize global resources for biodiversity finance. Canada will showcase its leadership through two Canadian-led official side events focused on innovative nature finance and the essential role of Indigenous leadership in advancing conservation efforts at home and around the world. The delegation will also take part in strategic bilateral meetings, high-level roundtables, and civil society events to strengthen cooperation, advance solutions, and drive action to halt and reverse biodiversity loss.

From November 9 to 20, 2026, in Antalya, Türkiye, Canada will participate in the 31st Conference of the Parties to the United Nations Framework Convention on Climate Change (COP31). Building on multilateral engagements, including the 10th Ministerial on Climate Action, Canada will continue working with international partners, Indigenous representatives, civil society, youth, and other stakeholders to strengthen the resilience of vulnerable communities; reduce methane emissions; accelerate electrification; and mobilize finance and investments from public and private sources. For the fifth consecutive year, Canada will host a national pavilion at COP31, showcasing Canadian climate leadership and innovation. The Canada Pavilion will serve as a hub for connection and collaboration.

Canada’s international leadership is backed by action at home. To accelerate electrification, Canada is building major clean energy projects across the country, including with the largest clean energy investment in North American history in Churchill Falls. Through A Force of Nature: Canada’s Strategy to Protect Nature and $3.8 billion in investments and funding, Canada is advancing its commitment to conserve 30% of lands and waters by 2030 through strong partnerships and innovative approaches to conservation. Canada recently reinforced this commitment by joining the 30×30 for Nature and People Ministerial Declaration at the 81st session of the United Nations General Assembly. Prime Minister, Mark Carney, recently announced a historic investment of $1.2 billion to better protect Canada’s oceans and the life they sustain. This will increase monitoring, strengthen ocean science and ecosystem protections, and improve marine incident prevention and preparedness. These priorities will be a key focus at both upcoming conferences.

Canada’s delegations to COP17 and COP31 will bring together the diverse perspectives from across Canadian society, including Indigenous representatives, civil society, the private sector, youth, and provincial and territorial government representatives. Working with international partners, these delegations help advance practical solutions to protect nature, strengthen resilience, and support sustainable economic prosperity.

Quotes

“Climate change and biodiversity loss are global challenges that no country can solve alone. At COP17 and COP31, Canada will work with partners from around the world to strengthen implementation of the Kunming–Montréal Global Biodiversity Framework and the Paris Agreement and collective efforts to address nature protection and climate change. Through international cooperation, Indigenous leadership, innovative solutions, and a collective commitment to conservation and climate action, we will build a sustainable future for people and nature alike.”
– The Honourable Julie Dabrusin, Minister of the Environment, Climate Change and Nature

“Nature loss is a global challenge that requires countries to work together and turn shared commitments into action. At COP17, Canada will share its experiences in advancing nature finance, including innovative approaches to valuing natural capital and mobilizing private investment for conservation. By exchanging ideas, lessons learned, and practical solutions with international partners, we can accelerate progress toward our global biodiversity goals and recognize nature as a foundation of long-term economic prosperity and resilience.”
– The Honourable Nathalie Provost, Secretary of State (Nature)

Quick facts

As the second largest country in the world, Canada has a vast amount of natural capital, including 24% of the world’s boreal forest, 37% of lakes, 25% of wetlands, and approximately 80,000 species. We have both a responsibility to steward these resources as well as a competitive advantage because of these assets.Canada hosted the 15th meeting of the Conference of the Parties to the United Nations Convention on Biological Diversity (COP15) in Montréal in 2022, which resulted in the adoption of the Kunming–Montréal Global Biodiversity Framework: an ambitious global plan to halt and reverse biodiversity loss by 2030.Canada supports the Armenian COP17 presidency and its approach to strengthen implementation of the Kunming–Montréal Global Biodiversity Framework toward meeting the Framework’s goals and targets.In September 2026, Canada and China co-chaired the Kunming Dialogue in Kunming, China. The Dialogue was a multilateral working-level meeting to discuss progress and challenges in the implementation of the Framework ahead of COP17.The Canada Pavilion at the United Nations Conference of the Parties (COP) is a key space to show Canadian climate leadership and innovation.Reducing methane emissions remains one of the fastest and most cost-effective ways to limit the rise of near-term global temperatures. Canada serves as co-convenor of the Global Methane Pledge, which counts 159 participating countries and the European Commission, with participants agreeing to take voluntary actions toward a collective goal of reducing global methane emissions at least 30% by 2030 (from 2020 levels).In April 2026, Canada announced a new goal of delivering $13 billion in international climate finance over the next five years.

Associated links

A Force of Nature: Canada’s Strategy to Protect NaturePrime Minister Carney Announces Historic Investment to Protect Canada’s OceansCanada Pavilion at the Conference of the Parties (COP)

Environment and Climate Change Canada’s X page
Environment and Climate Change Canada’s Facebook page
Environment and Natural Resources in Canada’s Facebook page
Environment and Climate Change Canada’s LinkedIn page
Environment and Climate Change Canada’s Instagram page

SOURCE Environment and Climate Change Canada

Continue Reading

Technology

DGEN TECHNOLOGIES (FORMERLY CHINA KELI ELECTRIC COMPANY) COMPLETES ACQUISITION AND NAME CHANGE AND FILES CSE LISTING STATEMENT

Published

on

By

VANCOUVER, BC, Oct. 16, 2026 /CNW/ — DGEN Technologies Corp. (formerly China Keli Electric Company Ltd.) (the “Company”) is pleased to announce that it has completed its previously announced acquisition of DGEN Financial Holdings Corp. (formerly DGEN Technologies Corp.) (“DGEN”) pursuant to a share exchange agreement dated December 9, 2025, as amended on August 17, 2026 (the “SEA”) on October 14, 2026 (the “Transaction”).

Pursuant to the Transaction, the Company acquired all of the issued and outstanding shares of DGEN in exchange for the issuance of an aggregate of 9,550,360 common shares of the Company (“Common Shares”) and 7,000,360 Common Share purchase warrants (“Warrants”) to certain former shareholders of DGEN. Each Warrant entitles the holder to acquire one Common Share at a price of $0.25 until October 14, 2028. As a result of the Transaction, DGEN became a wholly-owned subsidiary of the Company. As of the date hereof, the Company has 29,161,364 Common Shares and 7,000,360 Warrants issued and outstanding.

In connection with the completion of the Transaction, the Company changed its name from “China Keli Electric Company Ltd.” to “DGEN Technologies Corp.” and, hereinafter, will carry on the business of DGEN.

Listing Statement

Following the closing of the Transaction, the Company has filed a CSE Form 2A listing statement dated October 14, 2026 (the “Listing Statement”) on SEDAR+ under its profile relating to the Transaction and the proposed CSE listing. Investors are encouraged to review the Listing Statement, which provides detailed information about the Transaction, the Company and its operations.

The Company has received conditional approval to list the Common Shares on the Canadian Securities Exchange (the “CSE”) and has delisted the Common Shares from the TSX Venture Exchange in anticipation of listing on the CSE. The Common Shares are expected to commence trading on the CSE under the symbol “DGEN” on or about October 20, 2026.

Board of Directors and Management

Following completion of the Transaction, the directors and officers of the Company are Cole Goodwin, Chief Executive Officer and Director, Philip Lo, Chief Financial Officer, Corporate Secretary and Director, Sean Webster, Director, and Yee Man Cheung, Director.

Mr. Goodwin is a business executive with over 10 years of experience in alternative and traditional investment markets, financial technology and corporate operations. His experience includes senior management and board roles with publicly traded companies, including as Chief Operating Officer of Hyper Bit Technologies Ltd. Mr. Goodwin provides the Company with strategic and operational oversight in respect of its technology platform, including development and commercialization of payment infrastructure, integration of payment gateways, technology deployment and vendor management.

Escrow

At the time of listing, the Company will have 2,496,000 Common Shares and 1,000,000 Warrants held by related persons subject to escrow pursuant to an escrow agreement dated October 14, 2026 among the escrowed securityholders, the Company and Odyssey Trust Company, as escrow agent, subject to a 36-month release schedule pursuant to National Policy 46-201 – Escrow for Initial Public Offerings.

About DGEN Technologies Corp.

DGEN Technologies Corp. is a Vancouver-based technology company developing a cloud-based payment platform intended to integrate point-of-sale, kiosk and mobile payment systems into a unified and scalable solution. The Company’s platform is currently in beta stage and is operational, but has not yet been commercialized or generated revenue.

The CSE has not reviewed, approved, or disapproved, and does not accept responsibility for the adequacy or accuracy of the contents of this news release.

Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including, without limitation, statements with respect to: the expected listing of the Common Shares on the CSE; the satisfaction of any remaining conditions to listing; the business and operations of the Company following completion of the Transaction; the Company’s platform, including its development, commercialization, functionality, market adoption and ability to generate revenue; the Company’s intended business objectives; the escrow arrangements applicable to certain Common Shares and Warrants; and future plans and expectations of the Company. Forward-looking information is based on management’s current expectations, estimates, projections, beliefs and assumptions as of the date of this news release.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the possibility that the Common Shares may not commence trading on the CSE when expected or at all; risks relating to the Company’s early stage of development; the fact that the platform is in beta stage, has not yet been commercialized and has not generated revenue; risks associated with development, commercialization and market adoption of the platform; competition from established payment technology providers; reliance on third-party contractors and service providers; additional financing and dilution risks; market volatility; regulatory, compliance, cybersecurity and data privacy risks; risks relating to escrowed securities; and the other risks described in the Listing Statement. Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date of this news release. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

SOURCE DGEN Technologies Corp.

Continue Reading

Technology

ASSA ABLOY sells PKI business unit to Vista Equity Partners

Published

on

By

STOCKHOLM, Oct. 16, 2026 /PRNewswire/ — ASSA ABLOY has signed an agreement to sell HID’s PKI business unit to Vista Equity Partners (“Vista”).

The PKI business unit (Public Key Infrastructure) provides digital trust, identity, authentication, encryption, and certificate management solutions. The business unit includes PKI SaaS – IdenTrust and HydrantID – credential management, and ZeroSSL.

“I find it very satisfying that with Vista, the PKI business unit and its employees and customers gain a committed long-term investor, creating new opportunities for the future and I wish them every success,” says Nico Delvaux, President and CEO of ASSA ABLOY.

“Our PKI team has built a strong business with a strong customer base, and Vista has the expertise to take it forward as the market evolves,” says Björn Lidefelt, EVP and Head of HID. “We are pleased with this outcome for our customers, our employees, and for HID.”

The divested business had sales in 2025 of MUSD 58 (approx. MSEK 570) with a strong operating margin.

The divestiture is subject to customary closing conditions and is expected to close during the fourth quarter of 2026.

For more information, please contact: 
Nico Delvaux, President and CEO, tel. no: +46 8 506 485 82
Erik Pieder, CFO and Executive Vice President, tel. no: +46 8 506 485 72
Björn Tibell, Head of Investor Relations, tel. no: +46 70 275 67 68, e-mail: bjorn.tibell@assaabloy.com

About ASSA ABLOY
ASSA ABLOY is the global leader in access solutions. Every day we help people feel safe, secure and experience a more open world. We operate worldwide with 64,000 employees and sales of SEK 152 billion, with leading positions in areas such as efficient door openings, trusted identities and entrance automation. Our innovations enable safe, secure and convenient access to physical and digital places.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/assa-abloy/r/assa-abloy-sells-pki-business-unit-to-vista-equity-partners,c4410007

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/assa-abloy-sells-pki-business-unit-to-vista-equity-partners-302911635.html

Continue Reading

Trending